GlassScriptPhysician profile
Frank A Pensa
NPI 1760405450
$515.20
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2020: $51.19 · 2021: $34.05 · 2022: $89.78 · 2023: $20.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $149.47 | 2019-2020 | |
| Pfizer INC. | $48.20 | 2019-2022 | |
| Myovant Sciences INC. | $45.13 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $38.46 | 2019 | |
| Astellas Pharma US INC | $33.61 | 2019-2020 | |
| Becton, Dickinson and Company | $28.82 | 2019-2020 | |
| Covidien LP | $25.54 | 2019 | |
| Exeltis, USA INC. | $21.59 | 2022 | |
| Evofem Biosciences, INC. | $20.68 | 2022 | |
| Exact Sciences Corporation | $20.12 | 2023 | Cologuard Collection Kit |
| Amag Pharmaceuticals, INC. | $19.87 | 2019 | |
| Merck Sharp & Dohme LLC | $17.98 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.62 | 2019 | |
| Boston Scientific Corporation | $14.85 | 2019 | |
| Roche Diagnostics Corporation | $14.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Pensa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.